A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.
Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M, Noman MZ, Giustiniani J, Bellard E, Brayer S, Aguerre-Girr M, Meggetto F, Giuriato S, Malecaze F, Galiacy S, Jaïs JP, Chose O, Kadouche J, Chouaib S, Teissié J, Abitbol M, Bensussan A, Le Bouteiller P.
Chabot S, et al. Among authors: aguerre girr m.
J Exp Med. 2011 May 9;208(5):973-86. doi: 10.1084/jem.20100810. Epub 2011 Apr 11.
J Exp Med. 2011.
PMID: 21482699
Free PMC article.